MARKET

CNSY

CNSY

Cerenome, Inc
NASDAQ
3.520
-0.350
-9.04%
After Hours: 3.550 +0.03 +0.85% 19:39 08/03 EDT
OPEN
3.800
PREV CLOSE
3.870
HIGH
3.870
LOW
3.330
VOLUME
146.36K
TURNOVER
--
52 WEEK HIGH
23.43
52 WEEK LOW
2.900
MARKET CAP
24.23M
P/E (TTM)
-1.4102
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PSTV last week (0727-0731)?
Weekly Report · 21h ago
Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3
PUBT · 3d ago
Press Release: Cerenome Launches as an Integrated CNS Oncology Company
Dow Jones · 3d ago
Cerenome Launches as an Integrated CNS Oncology Company
Barchart · 3d ago
Weekly Report: what happened at PSTV last week (0720-0724)?
Weekly Report · 07/27 09:01
Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay
Benzinga · 07/21 11:35
Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, Kentucky
PUBT · 07/21 11:30
PLUS THERAPEUTICS - TO CHANGE NAME TO CERENOME, AND TICKER TO CNSY ON AUGUST 3, 2026
Reuters · 07/21 11:30
More
About CNSY
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Webull offers Plus Therapeutics Inc (USA) stock information, including NASDAQ: CNSY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNSY stock methods without spending real money on the virtual paper trading platform.